Royalty Pharma Acquires Remaining Evrysdi Royalty Interest for $240M Upfront
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Source: NASDAQ.COM
- Acquisition Completed: Royalty Pharma plc has finalized the acquisition of PTC Therapeutics' remaining royalty interest, making an upfront payment of $240 million and potentially earning up to $60 million in sales-based milestone payments, thereby solidifying its market position in the biopharmaceutical sector.
- Royalty Structure: This transaction grants Royalty Pharma 100% of the tiered royalty from Roche on worldwide net sales of Evrysdi, entitling it to 8% on sales up to $500 million and 16% on sales exceeding $2 billion, significantly enhancing its future revenue potential.
- Revenue Growth Expectations: Royalty Pharma anticipates beginning to receive the increased royalty in Q1 2026, based on Evrysdi product sales recorded in Q4 2025, which will provide a sustained cash flow and improve profitability for the company.
- Strategic Implications: This acquisition not only strengthens Royalty Pharma's portfolio in the rare disease treatment space but also reflects its confidence in Evrysdi's market potential, which is expected to drive long-term growth and enhance shareholder value.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on RPRX
Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 46.50 USD with a low forecast of 45.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 40.410
Low
45.00
Averages
46.50
High
48.00
Current: 40.410
Low
45.00
Averages
46.50
High
48.00
About RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva and Royalty Pharma Strike $500 Million Funding Agreement
- Funding Agreement: Teva and Royalty Pharma have established a funding agreement of up to $500 million to accelerate the clinical development of TEV-‘408, which is expected to significantly advance treatment options for immune-mediated diseases.
- Clinical Trial Progress: Preliminary data from the ongoing Phase 1b study of TEV-‘408 in vitiligo supports IL-15 as a potential therapeutic target, with results expected to be shared in 2026, potentially offering new therapies for various autoimmune conditions.
- Future Outlook: Teva anticipates flat to slightly declining sales in 2026 compared to 2025, but expects low-single digit growth in 2027 and mid-single digit CAGR by 2030, indicating long-term growth potential.
- Credit Rating Upgrade: In December 2025, S&P upgraded Teva's long-term issuer credit rating from BB to BB+ with a stable outlook, while Moody's affirmed its Ba1 rating and revised the outlook to positive, reflecting market confidence in Teva's future development.
Continue Reading
Teva Pharmaceuticals Secures $500M Deal with Royalty Pharma for TEV-408 Development
- Funding Agreement: Teva has entered into a funding agreement with Royalty Pharma for up to $500 million, including an initial $75 million to support a Phase 2b study in vitiligo, aiming to accelerate the development of TEV-408 to address significant unmet medical needs.
- Clinical Progress: TEV-408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, having received Fast Track designation from the FDA, indicating its potential to provide new treatment options for autoimmune diseases and possibly generate new revenue streams for Teva.
- Market Expectations: Teva anticipates revenues in the lower end of the $16.8–$17.0 billion range for 2025, with flat to slightly lower revenues in 2026 and low-single-digit growth in 2027, reflecting a strategic focus on stable growth in the coming years.
- Market Reaction: Despite a more than 6% pre-market gain in TEVA stock, retail sentiment on Stocktwits turned ‘bearish’, indicating cautious investor sentiment regarding the company's long-term growth potential amidst mixed market reactions.
Continue Reading